← Back to Clinical Trials
Recruiting NCT05927818

NCT05927818 Sentinel Lymph Node Biopsy in Early-Stage Ovarian Cancer

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05927818
Status Recruiting
Phase
Sponsor Istanbul University
Condition Sentinel Lymph Node
Study Type INTERVENTIONAL
Enrollment 100 participants
Start Date 2023-04-15
Primary Completion 2025-10-15

Eligibility & Interventions

Sex Female only
Min Age 18 Years
Max Age 90 Years
Study Type INTERVENTIONAL
Interventions
Sentinel lymph node biopsy (using sterile charcoal stain) in early ovarian cancer

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 100 participants in total. It began in 2023-04-15 with a primary completion date of 2025-10-15.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The primary goal of this prospective study is to define the efficacy of the sentinel lymph node biopsy (SLNB) procedure by comparing it to the results obtained from systematic lymphadenectomy, each performed in participants with a suspicious adnexal mass for early-stage ovarian cancer.

Eligibility Criteria

Inclusion Criteria: Must have a suspicious adnexal mass for early stage ovarian cancer Must be medically and surgically fit enough to perform SLNB and complete the systematic lymphadenectomy. \- Exclusion Criteria: Ovarian mass with low probability for early stage ovarian cancer. Medical or surgical contraindications for surgical comprehensive staging. Metastatic cancers or double primary cancers (metachronous) of ovary Recurrent ovarian cancer Preoperative or intraoperative finding of advanced ovarian cancer (FİGO stage III and IV) Neoadjuvant ovarian cancer \-

Contact & Investigator

Central Contact

Mustafa ALBAYRAK, MD

✉ mustafaalbayrak@icloud.com

📞 +90 532 687 10 51

Frequently Asked Questions

Who can join the NCT05927818 clinical trial?

This trial is open to female participants only, aged 18 Years or older, up to 90 Years, studying Sentinel Lymph Node. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05927818 currently recruiting?

Yes, NCT05927818 is actively recruiting participants. Contact the research team at mustafaalbayrak@icloud.com for enrollment information.

Where is the NCT05927818 trial being conducted?

This trial is being conducted at Istanbul, Turkey (Türkiye).

Who is sponsoring the NCT05927818 clinical trial?

NCT05927818 is sponsored by Istanbul University. The trial plans to enroll 100 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology